A new profile of substance abuse in adolescents and young adults;Um novo perfil de abuso de substâncias em adolescentes e jovens adultos

Acta Medica Portuguesa

Volumn 24, Issue 5, 2011, Pages 739-756

  Guerreiro, Diogo Frasquilho ^a   Carmo, Ana Lisa ^a   da Silva, Joaquim Alves ^a   Navarro, Rita ^a   Góis, Carlos ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; FLUNITRAZEPAM; KETAMINE; LYSERGIDE; METHAMPHETAMINE; OXYBATE SODIUM; STREET DRUG;

ADVERSE OUTCOME; ARTICLE; DATA BASE; HUMAN; KNOWLEDGE; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; ADDICTION; ADOLESCENT; ADULT; REVIEW;

ADOLESCENT; FLUNITRAZEPAM; HUMANS; KETAMINE; LYSERGIC ACID DIETHYLAMIDE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SODIUM OXYBATE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84857186302     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. MAXWELL JC: Party drugs: properties, prevalence, patterns, and problems. Subst Use Misuse 2005;40(9-10):1203-40
2. GC, MCCANCE-KATZ EF: A brief overview of the clinical pharmacology of club drugs. Subst Use Misuse 2005;40(9-10):1189-1201
3. COLFAX G, GUZMAN R: Club drugs and HIV infection: a review. Clin Infect Dis 2006;42(10):1463-9
4. Shulgin AT: The background and chemistry of MDMA. J Psychoactive Drugs 1986;18(4):291-304
5. GREER G, TOLBERT R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18(4):319-327
6. LAWN JC: Schedules of controlled substances: scheduling of 3,4 methylenedioxymethamphetamine (MDMA) into Schedule I. Federal Register 1988;51:36552-60
7. WOLFF K, HAY AW, SHERLOCK K, CONNER M: Contents of ecstasy. Lancet 1995;346:1100-1
8. SHERLOCK K, WOLFF K, HAY AW, CONNER M: Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med 1999;16(3):194-7
9. HAYNER GN, MCKINNEY H. MDMA: The dark side of ecstasy. J Psychoactive Drugs 1986;18(4):341-7
10. LD, O'MALLEY PM, BACHMAN JG, SCHULENBERG JE ed: Monitoring the Future national results on adolescent drug use: Overview of key findings, 2007 (NIH Publication No. 08-6418). Bethesda: National Institute on Drug Abuse 2008
11. European Monitoring Center for Drugs and Drug Addiction: General population surveys of drug use. Available from: http://stats04.emcdda.europa.eu/html.cfm/index5324EN.html [Acedido em Julho de 2008]
12. MARTINS SS, STORR CL, ALEXANDRE PK, CHILCOAT HD: Adolescent ecstasy and other drug use in the National Survey of Parents and Youth: the role of sensation-seeking, parental monitoring and peer's drug use. Addict Behav 2008;33(7):919-933
13. NICHOLS DE, OBERLENDER R: Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann N Y Acad Sci 1990;600:613-623; discussion 623-615[Está Certa esta Referência???]
14. Substance Abuse and Mental Health Services Administration. Office of Applied Studies: Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Administration, Office of Applied Studies 2007
15. COTTLER LB, WOMACK SB, COMPTON WM, BEN-ABDALLAH A: Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 2001;16(8):599-606
16. STEELE TD, MCCANN UD, RICAURTE GA: 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): pharmacology and toxicology in animals and humans. Addiction 1994;89(5):539-551
17. DE LA TORRE R, FARRE M, ROSET PN et al: Pharmacology of MDMA in humans. Ann N Y Acad Sci 2000;914:225-237
18. KRETH K, KOVAR K, SCHWAB M, ZANGER UM: Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 2000;59(12):1563-71
19. DE LA TORRE R, FARRE M, ORTUNO J et al: Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000;49(2):104-9
20. PARROTT AC: MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004;50(4):329-335
21. GUDELSKY GA, YAMAMOTO BK: Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 2008;90(2):198-207
22. TETER CJ, GUTHRIE SK: A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001;21(12):1486-1513
23. GREEN AR, CROSS AJ, GOODWIN GM: Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). Psychopharmacology (Berl) 1995;119(3):247-260
24. VOLLENWEIDER FX, GAMMA A, LIECHTI M, HUBER T: Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19(4):241-251
25. LIECHTI ME, BAUMANN C, GAMMA A, VOLLENWEIDER FX: Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000;22(5):513-521
26. UYS JD, NIESINK RJ: Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Drug Alcohol Rev 2005;24(4):359-368
27. ROTHMAN RB, BAUMANN MH, DERSCH CM et al: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39(1):32-41
28. RICAURTE GA, MCCANN UD: Recognition and management of complications of new recreational drug use. Lancet 2005;365(9477):2137-45
29. HALL AP, HENRY JA: Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006;96(6):678-685
30. CHEZE M, DEVEAUX M, MARTIN C, LHERMITTE M, PEPIN G: Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS. Application to the determination of MDMA after low ecstasy intake. Forensic Sci Int 2007;170(2-3):100-4
31. SCHIFANO F: A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 2004;173(3-4):242-8
32. HENRY JA, FALLON JK, KICMAN AT, HUTT AJ, COWAN DA, FORSLING M: Low-dose MDMA (ecstasy) induces vasopressin secretion. Lancet 1998;351:1784
33. ELLIS AJ, WENDON JA, PORTMANN B, WILLIAMS R: Acute liver damage and ecstasy ingestion. Gut 1996;38(3):454-8
34. LIEB R, SCHUETZ CG, PFISTER H, VON SYDOW K, WITTCHEN H: Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002;68(2):195-207
35. CAPELA JP, FERNANDES E, REMIAO F, BASTOS ML, MEISEL A, CARVALHO F: Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. Neurotoxicology 2007;28(4):868-875
36. CHIPANA C, CAMARASA J, PUBILL D, ESCUBEDO E: Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008;29(1):179-183
37. NUTT D: Neurobiology of addiction and implications for treatment. Br J Psychiatry 2003;182:97-100.
38. ZWEBEN JE, COHEN JB, CHRISTIAN D et al: Psychiatric symptoms in methamphetamine users. Am J Addict 2004;13(2):181-190
39. HUNT D, KUCK S, TRUITT L: Methamphetamine Use: Lessons Learned, final report to the National Institute of Justice. Washington 2006
40. NORDAHL TE, SALO R, LEAMON M: Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. Summer J Neuropsychiatry Clin Neurosci 2003;15(3):317-325
41. National Institute on Drug Abuse: Methamphetamine Abuse and Adiction. Bethesda: National Institute on Drug Abuse; 1998
42. SULZER D, SONDERS MS, POULSEN NW, GALLI A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75(6):406-433
43. ELSOHLY MA, JONES AB: Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug? J Anal Toxicol 1995;19(6):450-8
44. NIXON AL, LONG WH, PUOPOLO PR, FLOOD JG: Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 1995;41(6 Pt 1):955-6
45. VALENTINE JL, KEARNS GL, SPARKS C et al: GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. J Anal Toxicol 1995;19(7):581-590
46. KAYE S, MCKETIN R, DUFLOU J, DARKE S: Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007;102(8):1204-11
47. CHIN KM, CHANNICK RN, RUBIN LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006;130(6):1657-63
48. SPERLING LS, HOROWITZ JL: Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann Intern Med 1994;121(12):986
49. ALLDREDGE BK, LOWENSTEIN DH, SIMON RP: Seizures associated with recreational drug abuse. Neurology 1989;39(8):1037-9
50. OLSON KR, KEARNEY TE, DYER JE, BENOWITZ NL, BLANC PD: Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994;12(3):392-5
51. BARR AM, PANENKA WJ, MACEWAN GW et al: The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006 Sep;31(5):301-313.
52. WANG GJ, VOLKOW ND, CHANG L et al: Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 2004;161(2):242-8
53. MARTEL M, STERZINGER A, MINER J, CLINTON J, BIROS M: Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med 2005;12(12):1167-72
54. RICHARDS JR, DERLET RW, DUNCAN DR: Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med 1997;4(3):130-5
55. ROLL JM, PETRY NM, STITZER ML et al: Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 2006;163(11):1993-9
56. NEWTON TF, ROACHE JD, DE LA GARZA R et al: Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31(7):1537-44
57. ELKASHEF AM, RAWSON RA, ANDERSON AL et al: Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33(5):1162-70
58. MEIJLER MM, MATSUSHITA M, WIRSCHING P, JANDA KD: Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004;1(1):77-89
59. PASSIE T, HALPERN JH, STICHTENOTH DO, EMRICH HM, HINTZEN A: The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther Winter 2008;14(4):295-314
60. National Institute on Drug Abuse: Hallucinogens: LSD, Peyote, Psilocybin, and PCP. Nida InfoFact ed: National Institutes of Health 2008
61. US Drug Enforcement Administration (DEA): d-Lysergic Acid Diethylamide 2007
62. BORGWARDT S: Albert Hofmann, the father of LSD (1906-2008). Neuropsychobiology 2008;58(1):53-4
63. National Institute on Drug Abuse: Hallucinogens and Dissociative Drugs. Beteshda 2001; Report No.:01-4209
64. ABRAHAM HD, ALDRIDGE AM, GOGIA P: The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996;14(4):285-298
65. AGHAJANIAN GK, BING OH: Persistence of Lysergic Acid Diethylamide in the Plasma of Human Subjects. Clin Pharmacol Ther 1964;5:611-4
66. AGHAJANIAN GK, MAREK GJ: Serotonin and hallucinogens. Neuropsychopharmacology 1999;21(2 Suppl):16S-23S
67. NICHOLS D: Hallucinogens. Pharmacol Ther 2004;101(2):131-181
68. SCHIFF PL: Ergot and its alkaloids. Am J Pharm Educ 2006;70(5):98
69. HALPERN JH, POPE HG: Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003;69(2):109-119
70. STRASSMAN RJ: Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 1984;172(10):577-595
71. GABEL M, IANZITO BM: Treatment for ingestion of LSD. J Pediatr 1972;81(3):634-5
72. LERNER AG, FINKEL B, OYFFE I, MERENZON I, SIGAL M: Clonidine treatment for hallucinogen persisting perception disorder. Am J Psychiatry 1998;155(10):1460
73. European Monitoring Centre for Drugs and Drug Addiction: Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Lisbon 2002
74. LEUNG KS, COTTLER LB: Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry 2008;21(3):234-241
75. RILEY S, JAMES C, GREGORY D, DINGLE H, CADGER M: Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001;96:1035-47
76. REYNAUD-MAURUPT C, BELLO PY, AKOKA S, TOUFIK A: Characteristics and behaviors of ketamine users in France in 2003. J Psychoactive Drugs 2007;39(1):1-11
77. MUETZELFELDT L, KAMBOJ SK, REES H, TAYLOR J, MORGAN CJ, CURRAN HV: Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 2008;95(3):219-229
78. MOORE KA, SKLEROV J, LEVINE B, JACOBS AJ: Urine concentrations of ketamine and norketamine following illegal consumption. J Anal Toxicol 2001;25(7):583-8
79. KIM JY, IN MK, KIM JH: Determination of ketamine and norketamine in hair by gas chromatography/mass spectrometry using two-step derivatization. Rapid Commun Mass Spectrom 2006;20(20):3159-62
80. MORGAN CJ, MUETZELFELDT L, CURRAN HV: Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 2009;104(1):77-87
81. KL, DARRACOT-CANKOVIC R: The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs 2001;33(2):151-8
82. SNEAD OC, GIBSON KM: Gamma-hydroxybutyric acid. N Engl J Med 2005;352(26):2721-32
83. WEIR E: Drug-facilitated date rape. CMAJ 2001;165(1):80
84. ANDERSON IB, KIM SY, DYER JE et al: Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006 Feb;47(2):177-183.
85. Federal Register: Addition of gamma-hydroxybutyric acid to schedule I. Federal Register 2000:13235-8
86. SANGUINETI VR, ANGELO A, FRANK MR: GHB: a home brew. Am J Drug Alcohol Abuse 1997;23(4):637-642
87. European Monitoring Centre for Drugs and Drug Addiction: GHB and its precursor GBL: an emerging trend case study. EMCDDA thematic papers 2008; Available from: http://www.emcdda.europa.eu/publications/thematic-papers/ghb [Acedido em Abril de 2009]
88. GONZALEZ A, NUTT DJ: Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005;19(2):195-204
89. CRUNELLI V, EMRI Z, LERESCHE N: Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006;6(1):44-52
90. KINTZ P, GOULLE JP, CIRIMELE V, LUDES B: Window of detection of gamma-hydroxybutyrate in blood and saliva. Clin Chem 2001;47(11):2033-4
91. LI J, STOKES SA, WOECKENER A: A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998;31(6):729-736
92. CHIN RL, SPORER KA, CULLISON B, DYER JE, WU TD: Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998 Jun;31(6):716-722.
93. Tarabar AF, Nelson LS: The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004;23(1):45-9
94. WOODWORTH T: Abuse and Trafficking of Rohypnol. 1996 Available from: http://www.usdoj.gov/dea/pubs/cngrtest/ct960516.htm[Acedido em Abril de 2009]
95. INFARMED: Prontuário Terapêutico Online - Flunitrazepam; Available from: http://www.infarmed.pt/prontuario/index.php [Acedido em Abril de 2009]
96. ANGLIN D, SPEARS KL, HUTSON HR: Flunitrazepam and its involvement in date or acquaintance rape. Acad Emerg Med 1997;4(4):323-6
97. DARKE SG, ROSS JE, HALL WD: Benzodiazepine use among injecting heroin users. Med J Aust 1995;162(12):645-7
98. SIMMONS MM, CUPP MJ: Use and abuse of flunitrazepam. Ann Pharmacother 1998;32(1):117-9
99. RICKERT VI, WIEMANN CM, BERENSON AB: Prevalence, patterns, and correlates of voluntary flunitrazepam Use. Pediatrics 1999;103(1):E6
100. CALHOUN SR, WESSON DR, GALLOWAY GP, SMITH DE: Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas. J Psychoactive Drugs 1996;28(2):183-9
101. SCHWARTZ RH, WEAVER AB: Rohypnol, the date rape drug. Clin Pediatr (Phila) 1998;37(5):321
102. SAN L, TATO J, TORRENS M, CASTILLO C, FARRE M, CAMI J: Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug Alcohol Depend 1993;32(3):281-6
103. FARRE M, TERAN MT, ROSET PN, MAS M, TORRENS M, CAMI J: Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology (Berl) 1998;140(4):486-495
104. GAFNI I, BUSTO UE, TYNDALE RF, KAPLAN HL, SELLERS EM: The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol 2003;23(2):169-175
105. MINTZER MZ, GRIFFITHS RR: Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug Alcohol Depend 1998;53(1):49-66
106. LORD HL, RAJABI M, SAFARI S, PAWLISZYN J: Development of immunoaffinity solid phase microextraction probes for analysis of sub ng/mL concentrations of 7-aminoflunitrazepam in urine. J Pharm Biomed Anal 2006;40(3):769-780
107. DADERMAN AM, FREDRIKSSON B, KRISTIANSSON M, NILSSON LH, LIDBERG L: Violent behavior, impulsive decision-making, and anterograde amnesia while intoxicated with flunitrazepam and alcohol or other drugs: a case study in forensic psychiatric patients. J Am Acad Psychiatry Law 2002;30(2):238-251
108. DADERMAN AM, EDMAN G: Flunitrazepam abuse and personality characteristics in male forensic psychiatric patients. Psychiatry Res 2001;103(1):27-42
109. BRAMNESS JG, SKURTVEIT S, MORLAND J: Clinical impairment of benzodiazepines--relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend 2002;68(2):131-141